**Preventing deaths due to the hypertensive disorders of pregnancy**

Peter von Dadelszen, MBChB, DPhil, FRCOG, Professor and Academic Head of Obstetrics and Gynaecology

Laura A Magee, MD, MSc, FRCPC, Professor of Maternal Medicine

Institute of Cardiovascular and Cell Sciences, St George’s, University of London, and Department of Obstetrics and Gynaecology, St George’s University Hospitals NHS Foundation Trust, London, UK

**Address for correspondence:**

Professor Peter von Dadelszen, Room 0.27, Jenner Wing, St George’s, University of London, Cranmer Terrace, London SW17 0RE, UK; e-mail: pvd@sgul.ac.uk

**Abstract**

In this chapter, and taking a life cycle and both civil society- and medically-oriented approach, we will discuss the contribution of the hypertensive disorders of pregnancy (HDP) to maternal, perinatal and newborn mortality and morbidity. Here we review various interventions and approaches to preventing deaths due to the HDP and discuss effectiveness, resource needs and long term sustainability of the different approaches. Societal approaches, addressing Sustainable Development Goals (SDGs) 2.2 (malnutrition), 3.7 (access to sexual and reproductive care), 3.8 (universal health coverage), and 3c (health workforce strengthening), are required to achieve SDGs 3.1 (maternal survival), 3.2 (perinatal survival), and 3.4 (reduced impact of non-communicable diseases [NCDs]). Medical solutions require greater clarity around the classification of the HDP, increased frequency of effective antenatal visits, mandatory responses to the HDP when encountered, prompt provision of life-saving interventions and sustained surveillance for NCD risk for women with a past history of the HDP.

**Key words**

Hypertensive disorders of pregnancy

Chronic hypertension

Gestational hypertension

Pre-eclampsia

Community engagement

Food security

Autonomy of women

Reproductive choice

Mobile health

Task-shifting

Diagnosis

Risk stratification

Treatment

Non-communicable diseases

**A Introduction**

The hypertensive disorders of pregnancy (HDP), chronic (or pre-existing) hypertension, gestational hypertension and, especially, pre-eclampsia, remain leading causes of maternal and perinatal morbidity and mortality, as well as identifying individuals at increased risk for premature cardiovascular disease (1;2).

**A Diagnosis and classification**

Here we use the Canadian definitions and diagnostic criteria for, and classification of, the HDP (3).

Blood pressure (BP) should be measured at each antenatal visit. Hypertension in pregnancy is defined by a systolic BP (sBP) ≥140 mmHg and/or diastolic BP (dBP) ≥90 mmHg (3). Severe hypertension is defined as sBP≥160 mmHg (instead of 170 mmHg) as that level of sBP reflects stroke risk (3-7). Elevated BP should be confirmed by repeat measurement, at least 15 min apart, being measured three times; the first value being disregarded, and the average of the second and third taken as the BP value for the visit (3).

We suggest screening with urinary dipstick at each antenatal visit. Proteinuria diagnosis can be performed on random samples [by urinary dipstick or protein:creatinine ratio (PrCr)] or timed urine collections (usually 24h). Quantification of urinary protein by 24h urine collection is often inaccurate (8), and has been replaced by spot urine samples outside pregnancy (9). A dipstick value of ≥++ proteinuria and PrCr of ≥30 g/mol represent significant proteinuria of 0.3 g/d, the current if flawed, gold standard [SOGC 32]; a threshold up to 40 g/mol may be more appropriate in multiple pregnancy [SOGC 33,34]. Proteinuria should be quantified (by PrCr or 24h urine collection) if pre-eclampsia is suspected, as dipstick proteinuria <++ has a significant false-negative rate.

Chronic hypertension is defined as hypertension that pre-dates pregnancy, or appears before 20 weeks, or persists more than 3 months postpartum. It can be complicated by superimposed pre-eclampsia (3).

Gestational hypertension appears at ≥20 weeks and resolves by 3 months postpartum (3). Associated risks depend on gestational age at presentation and progression to pre-eclampsia; gestational hypertension at <34 weeks is associated with a ≈35% risk of pre-eclampsia which takes an average of 5 weeks to develop (3).

Pre-eclampsia is the HDP associated with the greatest risks, particularly when it is severe or present at <34 weeks (3;10;11). The risk of SGA infants is primarily among women who present at <34 weeks, with macrosomia more common with term pre-eclampsia (12). Pre-eclampsia is most commonly defined by new-onset proteinuria and potentially, other end-organ dysfunction. Table 1 outlines the end-organ dysfunction of pre-eclampsia: ‘adverse conditions’ and ‘severe complications.’ ‘Adverse conditions’ consist of maternal symptoms, signs, and abnormal laboratory results, and abnormal fetal monitoring results that may herald development of severe maternal or fetal complications (including stillbirth). The ‘adverse conditions’ are those for which we wait and to which we respond (e.g., low oxygen saturation) to avoid the severe complications that we wish to avoid entirely (e.g., pulmonary oedema). Remember that a significant minority of women will present with unheralded eclampsia (13). That response could be more intensive maternal or fetal monitoring, specific treatment, or delivery. In the Canadian rubric, ‘severe complications’ of pre-eclampsia warrant delivery, irrespective of gestational age (3).

It must be remembered that delivery does not ‘cure’ pre-eclampsia, it only initiates the recovery from the disease – and is the only intervention that will do so. Especially with early-onset pre-eclampsia, that arising before 34 weeks gestation, many women experience a transient deterioration in their clinical state, with nadirs in platelet count and renal function and maximal liver enzyme abnormalities, before their recovery. Frequently, this period of clinical vulnerability may last up to 72 hours postpartum (1;2). In more-developed countries, those women who die from the consequences of pre-eclampsia almost uniformly do so postnatally.

**A The global impact of pregnancy hypertension**

*B Maternal mortality*

Complicating an estimated 3-10% of pregnancies (1;2), it has been estimated that the HDP cause 30,000 maternal deaths annually (14). However, verbal autopsy data from Pakistan imply that up to 40% of women who die from postpartum haemorrhage (PPH) complained of symptoms of pre-eclampsia (e.g., headache, visual disturbances, and abdominal pain) or had seizures prior to the onset of their life-ending haemorrhage. It may be that a significant proportion of these women had pre-eclampsia that was complicated by disseminated intravascular coagulation, especially with the occurrence of abruption, but were never noted to be hypertensive by the formal health system. Such women will have bled sufficiently by the time of their presentation to mask their underlying hypertension; indeed, many will be hypotensive by the time they present for care. As PPH is estimated to cause 40,000 maternal deaths (14), the actual number of maternal deaths caused by the HDP may be as high as 46,000 annually. Over 99% of these deaths occur in less-developed countries (15).

As with most causes of maternal death, avoidable delays in triage, transport and treatment contribute to a majority of HDP-related maternal deaths (16). We believe that civil society has an important, and hitherto under-mobilised, role to play in overcoming these delays. This is an important theme to which we will return.

*B Maternal morbidity*

Approximately 30% of all maternal near-miss events will be due to pregnancy hypertension (17;18), with near-miss events complicating about 420/100,000 deliveries (19); approximately 230,000 HDP-related near-miss events per year (assuming 185 million pregnancies per annum).

*B Stillbirth*

Of the estimated 2.6 million stillbirths annually, approximately 16% occur in pregnancies complicated by pregnancy hypertension (20). Of particular importance to the global health community is the fact that 11% of stillbirths are associated with pregnancies complicated by chronic hypertension, while only 5% are associated with pre-eclampsia (presenting as either pre-eclampsia or eclampsia) (20). The global provision of effective antenatal surveillance could have a rapid impact on the association between chronic hypertension and stillbirth.

*B Neonatal mortality*

It has been estimated that the HDP precede 10% of early neonatal deaths (8/1000 live births) (21) and a significant proportion of late neonatal deaths (3/1000 live births) (22). This would approximate to about 1.5-2 million neonatal deaths annually.

*B Neonatal morbidity*

Due to their association with iatrogenic prematurity, fetal growth restriction and fetal overgrowth, the HDP are identifiable risk factors for newborn morbidity (e.g., respiratory distress and neonatal hypoglycaemia) (23). In addition, the rate of perinatal asphyxia, and resultant hypoxic-ischaemic encephalopathy, is increased due to the links between imperfect placentation and accelerated placental ageing with the HDP (24;25). Less-well recognised are the associations between maternal pre-eclampsia and neonatal thrombocytopoenia and neutropoenia (23). The rates of neonatal morbidity will be inversely-related to neonatal mortality rates, as survivability requires essential interventions that range from Kangaroo mother care to access to neonatal intensive care. As a rule of thumb, neonatal morbidities will occur 10-to-20 times more often than neonatal deaths.

**A Civil society-based solutions**

There is increasing recognition of the importance and value of preconception care (26). Women and, all too frequently, girls enter pregnancy within the continuum of their individual life cycle. In our opinion, too often has pregnancy been focussed upon as a singular event that begins with either conception or a positive pregnancy test. If the global community wishes to achieve the Sustainable Development Goal 3.1, to reduce the global maternal mortality ratio to less than 70 per 100,000 live births by 2030 [http://www.un.org/sustainabledevelopment/health/], we need to intervene now to alter young girls’ and women’s health and societal status.

How might such changes be achieved in the context of pregnancy hypertension? Here we elucidate some possible solutions.

*B Community engagement and mobilisation*

Prost and colleagues have assessed the effects of women's groups practising participatory learning and action, compared with usual care, on birth outcomes in low-resource settings in Bangladesh, India, Malawi, and Nepal (27). Exposure to women's groups was associated with a 37% reduction in maternal mortality, a 23% reduction in neonatal mortality, and a 9% trend towards a reduction in stillbirths. In a meta-regression analyses, the proportion of pregnant women in groups was linearly associated with reduction in both maternal and neonatal mortality, and if ≥30% of pregnant women participate in groups both maternal and neonatal mortality rates will fall (55% and 33%, respectively), in a cost effective manner.

Since that review, Colbourn and colleagues evaluated a rural participatory women's group community intervention (CI) and a quality improvement intervention at health centres (FI) via a two-by-two factorial cluster RCT (28). Following adjustment for clustering and stratification, the neonatal mortality rate was 22% lower in FI + CI than control clusters and the perinatal mortality rate was 16% lower in CI clusters. They were underpowered to assess maternal mortality.

Through the Community-Level Interventions for Pre-eclampsia (CLIP) cluster RCTs in Mozambique, Pakistan and India, we are testing the specific ability of HDP-oriented community engagement to improve maternal and fetal outcomes [http://www.thelancet.com/protocol-reviews/13PRT-9313]. In the interim, and as pre-eclampsia and eclampsia can be detected in the community, we suggest that the non-specific benefits of community mobilisation are likely to improve HDP-related health outcomes. Such mobilisation could most usefully include gaining prior permissions to respond to maternal health emergencies for women without autonomy of decision-making, transport planning, and micro-insurance initiatives to cover facility out-of-pocket expenses (29).

*B Food security for girls and pregnant women*

For women to be of adequate stature and be in good health prior to, and during, pregnancy they require food security from childhood – indeed, probably starting during fetal life and prior to their own conception. To achieve SDG 3.1 by 2030, we must provide food security to today’s girls. Short stature (<164cm) is associated with an approximate doubling of the risk for pre-eclampsia, especially severe disease (30;31). An excess of short stature is observed in women who were undernourished as girls (32). Preferential feeding of male children and men, compared with girls and women, is prevalent in many less-developed countries (33).

Women from a food insecure household are three times as likely to be severely obese compared with women from food secure households, after controlling for covariates age, race, income, education, marital status, and number of children (34).

Once pregnant, women from food insecure households gain 1.9kg more than women from food-secure households (34). In addition, Dean and colleagues have determined that maternal pre-pregnancy weight is a significant factor in the preconception period with underweight contributing to a 32% higher risk of preterm birth, while obesity more than doubles the risk for pre-eclampsia and gestational diabetes (32). Among nutrition-specific interventions, pre-conception folic acid supplements prevent 69% of recurrent neural tube defects, and multiple micronutrient supplements show promise to reduce the rates of congenital anomalies and risk of pre-eclampsia. While vitamin C and E supplementation does not decrease the risk of developing pre-eclampsia, adequate dietary intake of foods replete in antioxidants is associated with decreased rates of pre-eclampsia (35-37).

Both hypertension and pre-eclampsia are more common in pregnant girls and women who have insufficient intake of elemental calcium, an effect that is reversed with calcium replacement and supplementation (38;39). Indeed, in women with a history of severe pre-eclampsia, recent RCT data show that low-dose calcium replacement (500mg/d to bring total intake to 1g/d) in women between pregnancy lowers the mean diastolic BP (-2.6mmHg) compared with women taking a matched placebo (+0.8mmHg; mean difference -3.4 [95% CI -0.4 to -6.4], p=0.025) (40).

Using cross-sectional data from India’s third National Family Health Survey (NFHS-3, 2005-06) data were obtained from 39,657 women aged 15-49 years who had had a live birth in the five years preceding the survey (41). Women who had consumed either an adequately diversified diet or folate and iron supplements were approximately 35% less likely to report symptoms of either pre-eclampsia or eclampsia than women with inadequately diversified dietary intake. However, we recognise that personal recall of pre-eclampsia symptoms or diagnoses is vulnerable to recall bias.

In terms of perinatal outcomes, Bhutta and colleagues estimate that maternal undernutrition contributes to 800 000 neonatal deaths annually; stunting, wasting, and micronutrient deficiencies are estimated to underlie nearly 3·1 million child deaths annually (42). They conclude that continued investments in nutrition-specific interventions to avert maternal and child undernutrition and micronutrient deficiencies through community engagement and delivery strategies, including women’s empowerment, agriculture, food systems, education, employment, social protection, and social safety nets, can greatly accelerate progress in countries with the highest burden of maternal and child undernutrition and mortality.

*B Delayed marriage and delayed first pregnancy*

In many less-developed country societies, marriage occurs early and is followed, in short order, by a first pregnancy. Both these events are modifiable through changes in civil societal expectations of girls and women.

Obstetric outcomes have been determined for teenage pregnancies in Finland, a country with a low teenage delivery rate and comprehensive high-quality antenatal care. In this privileged setting, teenagers face increased risks of several obstetric complications including a trebling of the risk for developing eclampsia, while a 13-to-15 year olds have almost four times the odds for developing pre-eclampsia compared with women aged 20-24 years old (43). This adverse influence of teenage pregnancy on maternal and perinatal outcomes is even stronger, compared with women in their 20s, in less-developed countries.

Kumar and colleagues have observed that the majority of pregnant teenagers are primigravid (83.2% vs. 41.4%) (44). Gestational hypertension (11.4% vs 2.2%), pre-eclampsia (4.3% vs 0.6%) and eclampsia (4.9% vs 0.6%) are more common in teenagers than in women in their 20s. In terms of perinatal risks, teenage mothers have pregnancies complicated more frequently by low birth weight (50.4% vs 32.3%), premature delivery (51.8% vs 17.5%), stillbirth (1.9% vs 0.3%), neonatal morbidities (e.g., perinatal asphyxia (11.7% vs 1.9%), jaundice (5.7% vs 1.2%) and respiratory distress (1.9% vs 0.3%)), and neonatal mortality (3.8% vs 0.5%). Relating back to the discussion about food insecurity and its contribution to obesity, the risks for a woman to develop either pre-eclampsia or eclampsia increase significantly with increasing BMI and decreasing age. Extremely obese teenagers are almost four times as likely to develop pre-eclampsia and eclampsia when compared with non-obese women aged 20-24 (45).

There is convincing evidence that prior and prolonged exposure to paternal antigens may reduce the likelihood of pre-eclampsia (46). Sexual and reproductive practices that minimise maternal exposure to paternal seminal fluid prior to pregnancy have been associated with an increased risk of pre-eclampsia. For example, women above the highest 10th percentile of vaginal exposure to paternal semen have a 70% reduced odds of developing pre-eclampsia compared with women below the lowest 25th exposure percentile (46); these data being consistent with our growing understanding of the role of innate immunity in modulating trophoblast invasion during the first and second trimesters (1;2;47).

*B Birth spacing*

From primarily more-developed country literature, it is well-recognised that either too short (<2 years) or too long (>10 years) birth interval increases a woman’s risk for developing pre-eclampsia, especially recurrent disease (3). In a less-developed country setting, De Jonge and colleagues analysed 5,571 second or higher order deliveries in rural Bangladesh (48). Younger women, women who deferred their fertility and those who achieve higher order parities were less likely to experience short birth intervals. Women who were socioeconomically disadvantaged were more likely to experience a short birth interval and a previous adverse outcome appeared to motivate women to delay a future pregnancy. Very short birth intervals of less than 21 months more than double the odds of either a stillbirth or newborn death. Therefore, giving women reproductive choice is an important tool in reducing the HDP-related burden of adverse maternal and perinatal events.

*B Facilities*

An important element of societal responsibility to women whose pregnancies are complicated by the HDP are facility availability and enhancement. While community-based screening will identify women with hypertension, accessible and effective health facilities, staffed continuously by respectful and skilled health practitioners providing evidence-based care, are required to provide the essential life-saving interventions discussed in detail below. Commodity security for these diagnostic tools, medicines and emergency obstetric care provision is the responsibility of all levels of health systems, from local stock-taking through to regional and national governments (49).

Beyond the commodities required to modify disease-specific risks of stroke and eclampsia, facilities need to fulfil water, sanitation and hygiene (WASH) standards to provide safe care (50), especially as the only definitive method to initiate recovery from pre-eclampsia is delivery of the placenta (3). This requires either labour induction or Caesarean delivery, the safety of both of which are WASH-dependent. Campbell and colleagues have provided a carefully-framed conceptual framework linking WASH to improved maternal and reproductive health outcomes (51).

An example of how to mobilise funds for facility availability and enhancement is the experience of the Local Authority Transfer Fund in Kenya. This fund returns 5% of income tax to communities in a proportional manner that has improved both accountability and community autonomy. A consequence has been an improvement in government income tax-based revenues, as communities see the return on their taxation used to build such things as schools, health facilities, and transport infrastructure (52). Improvements across these infrastructures will lead to improved maternal and perinatal health outcomes.

**A Medical solutions**

*B Health human resources*

To support women during and after pregnancy, as well as their newborns, there needs to be an adequate health human resources infrastructure available to women wherever they live. Of the leading causes of maternal and perinatal mortality, the HDP are those most amenable to a community-oriented approach as there is usually a lead time between the onset of symptoms and signs of pre-eclampsia and the evolution to life-threatening and -ending complications.

Within communities, in CLIP, we are taking the approach of task-shifting the screening, initial diagnosis and initiation of lifesaving therapies to mobile health (mHealth)-supported community health care providers in women’s communities [http://www.thelancet.com/protocol-reviews/13PRT-9313]. These workers are agentes polivalentes elementares, lady health workers, and both accredited social health activists and auxiliary nurse midwives in Mozambique, Pakistan and India, respectively. An element of the mHealth-directed response to the detection of hypertension is either urgent (within 4 hours) or non-urgent (within 24 hours) transfer to referral facilities that provide comprehensive emergency obstetric care; the mHealth app, PIERS on the Move, has specific thresholds to guide women to seek urgent, rather than non-urgent, care [refs]. However, it is important to recognise the increasing burden being placed on such workers through task-shifting in many countries – if this cadre of workers is to remain effective and accept more tasks it requires an expansion in numbers and adequate support through pre-deployment training and ongoing professional development and supervision.

Once women reach health posts, primary health centres and inpatient facilities they require access to trained and effective nurses, midwives, physician assistants and doctors. For maternity care, the global call is for strengthening and expansion of the midwifery workforce (53). It is incumbent on whomever provides maternal and perinatal health care to do so respectfully and utilising the best evidence-based approach that local resources permit (54;55). Improving work environments will increase the likelihood of women receiving respectful care (56).

In all settings and at all levels, maternity care providers are obliged to undertake continuous professional development (CPD) tailored to their educational and skill levels – and national professional societies and ministries are obliged to provide CPD and the time to attend CPD courses.

*B Screening for HDP risk*

Approximately 1% of women will be living with chronic hypertension when they conceive, but, at a global level, most of them will be unaware of that. Therefore, routine antenatal BP measurement will identify hypertensive women, of whom many will be shown to have chronic hypertension as they remain hypertensive beyond 6 weeks postpartum.

The strongest clinical markers of pre-eclampsia risk identifiable at antenatal booking are recommended for screening for pre-eclampsia in the community (3). Of nine clinical predictors of pre-eclampsia among nulliparous women carrying singleton pregnancies, one is protective (miscarriage at ≤10 weeks with same partner) and eight increase risk (younger maternal age, higher BP, higher BMI, family history of pre-eclampsia or coronary heart disease, woman with lower birthweight themselves, vaginal bleeding during early pregnancy, and short duration of sexual relationship); half of women destined to develop pre-eclampsia would be detected using the model (3). First trimester uterine artery Doppler, shows promise but needs further ‘real life’ evaluation (3).

Second and third trimester markers of pre-eclampsia risk include measures of: placental perfusion, vascular resistance, and morphology, maternal cardiac output and systemic vascular resistance, fetoplacental unit endocrinology, maternal renal function, maternal endothelial function and endothelial-platelet interaction, oxidative stress, circulating angiogenic factors; and glycosylated fibronectin (1-3;47;57). Other than direct clinical measurements of BP and proteinuria, most of these tests are limited to well-resourced settings. As no single test predicts pre-eclampsia with sufficient accuracy to be clinically useful (1-3;58), interest has grown in researching multivariable models that include clinical and laboratory predictors available at booking and thereafter (1-3;59). We await the results of definitive studies.

*B Prevention of pre-eclampsia*

C Calcium replacement and supplementation

Lassi and colleagues have systematically reviewed calcium supplementation (1-2g/d) for the prevention of pre-eclampsia and determined that calcium supplementation significantly reduces the risk of pre-eclampsia by 55% and by 64% in women with low dietary intake of calcium (60). In addition, calcium supplements have a significant protective effect on maternal mortality and serious morbidity and preterm birth; with trends to lowering risks for low birthweight and stillbirth.

Since this review, Hofmeyr and colleagues have reviewed the RCTs of calcium replacement (<1g/d), rather than supplementation (1-2g/d) (39). Pre-eclampsia was reduced consistently by an average 62% with replacement, with or without co-supplements. Overall results were consistent with the single quality trial of calcium replacement alone. Of note, one small trial of 60 women observed a statistical trend of >90% reduction in miscarriage risk for women taking calcium replacement combined with antioxidants commencing at 8–12 weeks. These limited data are consistent with calcium replacement reducing the risk of pre-eclampsia. Currently, Professor Hofmeyr is conducting the Calcium And Pre-eclampsia (CAP) trial assessing the ability of pre-pregnancy calcium replacement to prevent recurrent pre-eclampsia [http://www.thelancet.com/protocol-reviews/11PRT-4028]. Establishing a lower dose would have significant implications for current guidelines and their global implementation.

C Antiplatelet agents (low dose aspirin) for prevention of pre-eclampsia

Results of the Lassi review show that antiplatelet agents are associated with a consistent reduction in pre-eclampsia (17% reduction), preterm births <34 weeks (8% reduction), and a 14% reduction for all types of perinatal deaths (fetal, neonatal, infant) (60). We recommend that antiplatelet agents should be given to pregnant women at high risk of pre-eclampsia or those with gestational hypertension, since they lead to reduction of vast adverse outcomes of pregnancy both for the mother and newborn.

*B Provision of antenatal care*

While access to both antihypertensives and magnesium sulphate clearly matter, in our opinion the greatest health system priority to improve maternal and perinatal outcomes is the provision of effective maternity care. The WHO four visit model is associated with increased risks of perinatal loss (61), and this probably relates to the gap in antenatal surveillance between 36 weeks and delivery. Most HDPs present or deteriorate either near or at term. The accelerating pattern of antenatal visits (four-weekly visits until 28 weeks, fortnightly to 36 weeks, and weekly thereafter) was designed in Edinburgh largely for the identification of pre-eclampsia to afford the opportunity for timely delivery (62). Since the first triennial report of the UK Confidential Enquiries into Maternal Deaths (1952–54), pre-eclampsia- and eclampsia-related deaths have fallen by approximately 90% (63). Over 90% of that fall was achieved prior to the introduction of either effective antihypertensives for the management of pregnancy hypertension (64) or the use in the UK of magnesium sulphate for eclampsia prevention and treatment following the Collaborative Eclampsia and Magpie Trials, respectively (65;66). Once a diagnosis has been made, then an adequate health system can respond through the provision of inpatient care, ongoing surveillance, blood pressure control, seizure prophylaxis and timed delivery. Similar data exist for Sri Lanka following the introduction of comprehensive maternity care, including vital registration, registration of midwives, prenatal coverage (health centre- and home-based), and facility strengthening (67). Therefore, personalised risk assessment through antenatal care is an effective tool for reducing adverse pregnancy outcomes, especially when included in a package of health service enhancements.

*B Detection of the HDP*

C Blood pressure

BP measurement remains a cornerstone of the screening for, and diagnosis of, pre-eclampsia (3;63;68). An important advance in the move toward offering every pregnant woman accurate BP measurement and detection of pregnancy hypertension has been the development of the semi-automated Microlife BP 3AS1-2 sphygmomanometer®, which has been validated in women with the hypertension of pre-eclampsia (69). This device avoids the errors intrinsic in manual BP measurement in pregnancy (especially terminal digit preference (70)), can be used by minimally trained community-level health-care providers and costs less than $25 USD per unit.

C Urinary protein measurement

The obstetric gold standard of 24h urine collection is frequently inaccurate and not a precise measure of either proteinuria or creatinine clearance (8). Additionally, a recent systematic review of the spot protein:creatinine (PrCr) and albumin:creatinine (ACR) ratios as diagnostic tests for significant proteinuria (compared with 24h collection) in hypertensive pregnant women determined that the spot PrCr ratio (cutoff point, 30g/mol) is a reasonable “rule-out” test for detecting significant proteinuria of 0.3 g/day or more in hypertensive pregnancy (71). Practitioners using either 24h collections and/or the PrCr ratio in pregnancy must be particularly aware of the interaction between the protein estimation method and urinary concentration, as the pyrocatechol violet-dye method is vulnerable to overestimating urinary protein in dilute urine (63). Information related to the use of the ACR in pregnant women remains insufficient to guide practice (63). In pregnancy, urine is often dilute, and we found that almost 25 % of ACR results are clinically uninformative (72).

Within the PIERS cohort, dipstick proteinuria performs as well (or poorly) as other methods of assessing proteinuria for prediction of adverse outcomes (73). Our findings support the view that once significant proteinuria has been identified (by either dipstick [≥++], PrCr ratio or 24h collection), further proteinuria assessment should not be used to guide clinical decision-making related to either short- or long-term maternal prognosis. Rather, the serum creatinine value should be used to monitor renal function and risk in women with pre-eclampsia (11). In settings without laboratory support, the heaviness of dipstick proteinuria is predictive of adverse perinatal, but not maternal outcomes (10).

*B Time-of-disease maternal risk assessment*

Not all women with pregnancy hypertension are destined to either die or suffer permanent sequelae. Therefore, our Pre-eclampsia Integrated Estimate of RiSk (PIERS) initiative has been investigating tools to provide personalised risk assessment and medicine to women who have a diagnosis of a HDP. In the studies summarised below, the outcome of interest was maternal mortality or other serious complications of pre-eclampsia (11).

We have assessed the performance of maternal symptoms, proteinuria, oxygen saturation by pulse oximetry (SpO2), uric acid, platelet counts and liver tests individually to identify those hypertensive pregnant women who are more likely to suffer severe complications (73-78). Of these, only SpO2 showed any capacity as a test that can be used in isolation, including predicting non-cardiorespiratory adverse maternal outcomes. (area under the receiver-operator characteristic [AUC ROC] >0.7) (77). Therefore, we deemed that multivariable models were required.

C Resource-constrained settings

We developed and validated the demographics-, symptom- and sign-based miniPIERS risk prediction model to provide a simple, evidence-based tool to identify pregnant women in resource-constrained settings at increased risk of death or major hypertensive-related complications (10). Developed and validated on 2,081 women with any HDP admitted to a participating centre in Brazil, Fiji, Pakistan, South Africa and Uganda, the final miniPIERS model included: parity (nulliparous versus multiparous); gestational age on admission; headache/visual disturbances; chest pain/dyspnoea; vaginal bleeding with abdominal pain; systolic blood pressure; and dipstick proteinuria. The miniPIERS model was well-calibrated and had an area under the receiver operating characteristic curve (AUC ROC) of 0.77. External validation AUC ROC using the fullPIERS cohort (below) was 0.71. A predicted probability ≥25% to define a positive test classified women with 85.5% accuracy. Our conclusion is that miniPIERS can be used to identify women who would benefit most from interventions such as magnesium sulphate, antihypertensives, or transportation to a higher level of care.

To strengthen miniPIERS, we used South African and Pakistani data to recalibrate and extend miniPIERS to include SpO2 (79). Women with SpO2 < 93% had a 30-fold increase in risk of adverse maternal outcome compared with those with SpO2 > 97%. After recalibration and extension, the miniPIERS model including SpO2 (vs. not including SpO2) had improved sensitivity (32.8% vs. 49.6%) at the cost of minimally decreased specificity (91.5% vs. 96.2%).

In the CLIP trials we are testing the performance of miniPIERS, and other thresholds that mandate an urgent response, using country-specific versions of the PIERS on the Move (POM) app (80;81). The POM app provides culturally-sensitive, easy-to-use guidance for community health care providers. In rural Sindh, for example, a lady health worker is guided through antenatal screening, BP measurement and, if the pregnant woman is hypertensive, a range of responses that can include lady health worker-administered magnesium sulphate (for women at high risk) and, if the woman is severely hypertensive, oral methyldopa, prior to urgent referral for definitive facility-based care. If the woman is assessed as having less risk then she is advised to seek facility-based care within 24 hours.

C Well-resourced settings

We developed and internally-validated the fullPIERS model with the aim of identifying the risk of fatal or life-threatening complications in women with pre-eclampsia within 48h of hospital admission to tertiary obstetric centres in Australia, Canada, New Zealand, and the UK (11). Independent predictors of adverse maternal outcome included in fullPIERS are gestational age; chest pain or dyspnoea; SpO2, platelet count, and serum creatinine and aspartate transaminase concentrations. fullPIERS predicted adverse maternal outcomes within 48h of study eligibility (AUC ROC 0·88) and performed well (AUC ROC >0·7) up to 7 days after eligibility. In addition, we reassessed the performance of fullPIERS using predictor variables obtained within 6 and 24 hours of admission, and found that the stratification capacity, calibration ability, and classification accuracy of the model remained high (82).

Akkermans and colleagues performed an external validation of fullPIERS using prospectively-collected data from two tertiary care obstetric centres that participated in the Pre-eclampsia Trial Amsterdam (PETRA) (83) and observed that fullPIERS predicted adverse maternal outcomes within 48h (AUC ROC 0.97) and up to 7d after inclusion (AUC ROC 0.80). More recently, in prospective external validation cohort in India, women with a >30% predicted probability were 17.5-times more likely to experience adverse maternal outcome, implying that fullPIERS has particular strength as a “rule-in” test (84). Further external and temporal validation of fullPIERS is underway, and a fullPIERS mHealth app being developed.

*B Time-of-disease fetal risk assessment*

C Resource-constrained settings

The primary method for detection of the at-risk fetus has been maternal awareness of decreased fetal movement. Winje and colleagues have performed a systematic review of randomised and non-randomised studies assessing the effects of interventions to enhance maternal awareness of decreased fetal movement (85). Results were not pooled due to substantial heterogeneity between studies. Three RCTs and five non-randomised studies (NRSs) assessed the effects of interventions on stillbirth and perinatal death. RCT data are inconclusive for the prevention of stillbirth. All NRSs favoured intervention over standard care; three studies reported significant, while two reported non-significant, reductions in stillbirth or perinatal deaths. Therefore, on balance, the evidence supports awareness of fetal movement being beneficial.

In addition to fetal movements, within the PIERS initiative, we have developed and internally validated a prognostic model for perinatal death that could guide community-based antenatal care of women with a HDP in low-resourced settings as part of a mobile health application (86). Of 1688 women admitted ≥32+0 weeks gestation with a HDP from the five low-resourced countries in the miniPIERS cohort, 110 (6.5%) suffered a perinatal death. A logistic regression-derived model to predict perinatal death included maternal age; a count of symptoms (0, 1 or ≥2); and dipstick proteinuria. The AUC ROC is 0.75. The model, which excluded fetal movements due unavailability of that variable, correctly identified 42/110 (38.2%) additional cases as high-risk (probability >15%) of perinatal death compared with use of only gestational age.

C Well-resourced settings

Most experts suggest that the use of non-stress tests/cardiotocography (NST/CTG) be restricted to high-risk groups only, including women with pre-eclampsia (12). However, evidence is lacking to either support this practice or guide the practitioner on the frequency of testing. Most authorities suggest that women with mild pre-eclampsia undergo weekly NST/CTG, whereas those with severe early-onset pre-eclampsia (in particular in the presence of fetal growth restriction or oligohydramnios) be followed at least twice weekly (12). The authors of a recent Cochrane review concluded that ‘there is almost no evidence to date to indicate an optimal antenatal surveillance method for infants identified with impaired growth (87), highlighting the urgent need for research in this area.

In the context of both pre-eclampsia and IUGR, the use of the biophysical profile tends to falsely-reassure, leading to an excess of adverse perinatal events [(88-90).

Doppler velocimetry can be used in the assessment of fetuses from high-risk pregnancies, including IUGR and pre-eclampsia (particularly early-onset disease). Umbilical artery Doppler assessment in high-risk pregnancies is associated with a 29% reduction in perinatal mortality, as well as 10% fewer inductions of labour and Caesarean deliveries (12). The combination of abnormal middle cerebral artery peak systolic velocity and reversed flow in the ductus venosus increases the risk of perinatal mortality by 10-fold (12).

At this time, the available evidence suggests that, in cases of pre-eclampsia associated with IUGR, integrating Doppler, NST/CTG and fluid assessment may help further define the risk of perinatal death and assist in determining the optimal timing of delivery (12). However, as there is no outcome prediction model that integrates and weights the independent value of each of these parameters, we believe that research to develop and validate a fullPIERS-like model for high risk fetuses is required.

*B Treatments*

C Non-severe hypertension

BP-pressure targets for women with non-severe hypertension during pregnancy have been much debated. The Control of Hypertension In Pregnancy Study (CHIPS) trial was an open, international, multicentre RCT (91). CHIPS recruited 987 women at 14+0-33+6 weeks who had non-proteinuric chronic (74.6%) or gestational (25.4%) hypertension, an office dBP of 90-105mmHg (or 85-105mmHg if taking antihypertensive medications), and a live fetus, to receive either less-tight (target dBP 100mmHg) or tight (target dBP 85mmHg) control. The rates of pregnancy loss or high-level neonatal care >48h during the first 28 postnatal days did not differ between the less-tight and tight control groups (31.4% and 30.7%, respectively), and neither did maternal complications (3.7% and 2.0%, respectively), despite a mean dBP that was higher in the less-tight-control group by 4.6 mm Hg. Severe hypertension (≥160/110 mm Hg), a threshold for stroke risk, developed in 40.6% of the women in the less-tight-control group and 27.5% of the women in the tight-control group – a difference that is highly significant, both statistically and, for women, clinically.

In CHIPS, methyldopa and labetalol were used commonly both at randomisation (24.6% and 24.6%, respectively) and post-randomisation (22.8% and 44.1%, respectively). Following adjusted analyses, methyldopa (versus labetalol) at randomisation was associated with fewer babies with a birthweight <10th centile. Methyldopa (versus labetalol) post-randomisation was associated with fewer CHIPS primary outcomes, birthweight <10th centile, severe hypertension, pre-eclampsia, and delivery before both 34 and 37 weeks (92).

While CHIPS was limited to non-proteinuric women with hypertension, we believe that the results are relevant to women with pre-eclampsia. On balance, we believe that tight control is the preferred response for all types of pregnancy hypertension, especially in resource-constrained settings where access to follow-up and surveillance is more limited. This approach is not deleterious to the fetus, adds maternal safety by keeping women away from severe hypertension, and is consistent with approaches outside pregnancy. Methyldopa appears to be the preferable agent due to its effects, presence of essential medicines lists (93) and, for under-resourced settings, cost; other options are listed in Table 2. Note that angiotensin-converting enzyme inhibitors (e.g., captopril) and angiotensin-2 receptor-blockers (e.g., lisinopril) should not be used due to the increased risk of stillbirth with their use (3;64).

C Severe hypertension

A sBP ≥160mmHg and/or dBP ≥110mmHg requires a response, with immediate targets being to lower blood pressure to under those thresholds within hours (1;3;64;68). Severe systolic hypertension is an independent risk factor for stroke in pregnancy (4-7). The UK ‘Confidential Enquiries into Maternal Deaths’ has identified failure to recognize the severity of and to treat the severe (particularly systolic) hypertension of pre-eclampsia as the single most serious failing in the clinical care of those women who died from strokes (6;7).

Such acute elevations in blood pressure may reflect either the development or progression of pre-eclampsia and should precipitate detailed clinical, laboratory and ultrasound assessment of the pregnancy.

Our antihypertensive-of-choice for severe pregnancy hypertension is oral nifedipine (either capsule or intermediate-acting tablet) because it has a more reliable effect than both labetalol and hydralazine and the less frequent occurrence of drug-induced hypotension (63). Nifedipine is safe to use with concurrent magnesium sulphate (63). Our preference is for oral agents in non-obtunded women as their use can be initiated by nurses/midwives rather than the common requirement for doctor’s presence for an intravenous agent; the presence of a doctor can be delayed because of concurrent activities such as Caesarean deliveries.

Within the context of the PRE-EMPT initiative, Gynuity Health Projects are conducting a RCT with a head-to-head comparison of three oral antihypertensives for severe pregnancy hypertension, nifedipine, labetalol and methyldopa (http://pre-empt.cfri.ca/treatment/treatmentgynuity-trial). The results of this trial will be pertinent to all caregivers.

As a rule of thumb, our approach is to reserve nifedipine for use in women with severe pregnancy hypertension and to use either labetalol and/or methyldopa for longer term medication to achieve synergism of effect and to use beta-blockade to avoid the acute cardiovascular risks associated with nifedipine capsules. In addition, if a woman experiences an acute elevation in her blood pressure on, say, labetalol, it seems logical to us not to use more of that agent for acute blood pressure control. Effective antihypertensives are available in all settings to manage severe pregnancy hypertension (63;64) (Table 2).

C Prevention and treatment of seizures

Magnesium sulphate is the first-line treatment of eclampsia and its prevention, especially in women with severe disease (3;68). We reviewed current less-developed country regimens for magnesium sulphate (94). The commonly-used regimens are: 14g Pritchard loading dose (4g iv + 10g im), full Pritchard regimen (same loading dose + 5g/4h im maintenance), an im loading dose only regimen (10g im; without the 4g iv), the Zuspan regimen (4g iv loading dose + 1g/h iv) and the Sibai regimen (4g iv loading dose + 2g/h). Most regimens use additional 2g iv/im if seizures occur after initiation of therapy. The Zuspan regimen then increases the maintenance dose to 2g/h.

In terms of task-shifting, a single RCT of community administration of a magnesium sulphate loading dose before referral to a facility versus limiting treatment to facilities reduced the occurrence of recurrent eclampsia by 78%. Due to concerns related to maternal safety, cost and resource availability, there has been an interest in alternative regimens for magnesium sulphate administration, particularly in less-developed countries; however, we do not support moving to abbreviated or lower dose courses until adequately-powered and well-designed RCTs have been published (63;94). In addition, clarifying exactly who among women with non-severe pre-eclampsia requires magnesium sulphate, how much women should receive, and for how long remains a research priority.

We believe that the continued use of benzodiazepines, phenytoin, or lytic cocktail to be dangerous and requiring robust and sustained efforts by national societies and health administrators to be halted.

C Fetal neuroprotection

In addition to its use for eclampsia prophylaxis and treatment, in women with pre-existing or gestational hypertension, magnesium sulphate should be considered as a cost-effective therapy to decrease the risk of cerebral palsy (and ‘death or cerebral palsy’) in the setting of ‘imminent preterm birth’ (within the next 24 h) up to 33+6 weeks (95;96). We advocate using the same regimen for fetal neuroprotection as clinicians use for eclampsia prevention and treatment. This will reduce dosing errors and strengthen confidence in magnesium sulphate use.

Magnesium sulphate for fetal neuroprotection should not be used concurrently with tocolysis. Its use should be limited to when the clinician is certain of early preterm birth – the loading dose alone appears to be effective.

C Antenatal corticosteroids

When administered at ≤34+6 weeks, antenatal corticosteroids accelerate fetal pulmonary maturity and decrease neonatal mortality and morbidity, including women with HDPs (3). RCTs that administered steroids at 33+0 to 34+6 weeks resulted in reduced neonatal RDS (3), a subject of ongoing trials. The beneficial effects of steroids can be observed when the first dose is administered as late as within 4h before birth. As long as dating is secure, there is no evidence of short- or long-term maternal or fetal adverse effects of a single course of antenatal corticosteroids. Inaccurate dating and the use of corticosteroids close to term may cause harm (97).

If expectantly managed, women with pre-eclampsia remote from term (usually <34+0 weeks) will be delivered within two weeks of corticosteroid administration, but the duration of pregnancy prolongation varies from hours to weeks. All eligible women with pre-eclampsia should receive antenatal corticosteroids. If women with pre-eclampsia remain pregnant seven or more days after their initial course, then a single, and only a single, rescue course of corticosteroids appears to be warranted (98).

C Fluids

Routine preloading with a fixed volume of crystalloid (i.e., 500–1000 mL) will not prevent BP falls in normal women prior to Caesarean delivery (3); no specific studies exist for HDPs. Preloading may increase the risk of life-threatening pulmonary oedema (3). Hypotension should be treated with vasopressors as an infusion or small boluses (3).

Oliguria (<15 mL/h) is common in pre-eclampsia, particularly postpartum. In the absence of pre-existing renal disease or a rising creatinine, oliguria should be tolerated over hours, to avoid volume-dependent pulmonary oedema (3). Fluid balance should be closely monitored, and frusemide limited to pulmonary oedema treatment (3).

C When to deliver

In response to the new Canadian definition of severe pre-eclampsia, any woman with severe pre-eclampsia should be delivered (3;63). The manner of that delivery will be determined by the woman’s gestational age and other obstetric factors.

D At term

Women at term (≥36+0 weeks) with either pre-eclampsia or non-proteinuric gestational hypertension are best managed by a policy of induction of labour (3;63). Among women randomized ≥37+0 weeks, for every seven labour inductions there was one fewer Caesarean delivery. Among women with chronic hypertension appear to benefit most from induction at 38+0-39+6 weeks (99).

D Near term

However, a policy of induction near term (34+0-36+6 weeks) is associated with no measurable benefit for mothers, but with 3-fold greater risks of newborn respiratory distress (3).

D Remote from term

Remote from term, randomized controlled trial (RCT), case-control and cohort data support a policy of expectant (versus interventionist) care (63). Generally, about half of women will remain undelivered 48h after presentation (timeframe for antenatal corticosteroid administration and effect) and be eligible for expectant management. In RCTs, the in utero time gained from eligibility to delivery is about 14 days, whereas in non-RCT studies, the time gained is generally 7–10 days.

Expectant management should only be attempted in institutions experienced in the management of pre-eclampsia. Failure to provide obsessive surveillance during expectant management is a life-threatening gap in care (63). For women who present before 24 weeks’ gestation (or local limits of viability), expectant management is unlikely to offer any perinatal advantages while maternal risks persist and rise (63). For such women with pre-viability pre-eclampsia, the offer of pregnancy termination for maternal indications should be made. This remains an option denied women in many societies where full reproductive choice is withheld.

When a decision is made to pursue delivery at term gestational ages, vaginal delivery is a viable option if the maternal and fetal conditions allow it, although Caesarean delivery rates are significant (14–19%) (100). At lower gestational ages, rates of successful vaginal delivery are better than might be anticipated: 69% at 32+0-33+6 weeks and 48% between 28+0-31+6 weeks. However, vaginal delivery is rarely achieved at less than 28 weeks (7%) (100).

*B Long term health and non-communicable diseases: addressing the SDGs between generations*

C The mothers

Women who develop a HDP, deliver preterm and a baby with the lowest quintile of birthweight acquire similar risk for premature cardiovascular disease as women who smoke (101).

Any weight gain between pregnancies predicts pre-eclampsia and other pregnancy complications (3). Observational data suggest that in women who are morbidly obese, bariatric surgery lowers rates of subsequent HDP (3). Women with pre-existing hypertension should receive recommended cardiovascular risk factor screening and treatment (3).

As pregnancy is a biological ‘stress test’ of sorts, women with a prior HDP (particularly associated with preterm delivery or adverse perinatal outcome) should be informed of their increased future health risks, including; hypertension; cardiovascular and cerebrovascular morbidity and mortality; subsequent renal disease; thromboembolism; hypothyroidism; and type 2 diabetes mellitus (3). Barriers to compliance with a healthy diet and lifestyle include poor postpartum physical and psychological recovery, and lack of postpartum medical and psychological support from healthcare providers (3). These barriers need to be addressed in a way that is both culturally-responsive and effective.

C The offspring

The increasingly-robust evidence for developmental origins for health and disease is of particular importance as the world moves to embrace the SGDs. Approximately 20% of a person’s risk for premature cardiovascular disease is determined by birth. Girls who are born small due to the modifiable sociocultural factors discussed above are more likely to have pregnancies complicated by HDPs as well as premature cardiovascular disease. Interventions across the spectrum are likely to create a virtuous cycle that will accelerate progress towards the non-communicable disease elements of the SDGs.

Pre-eclampsia is a robust predictor of cardiovascular and reproductive health in the offspring of those pregnancies (3).

D Effects of maternal hypertension and its therapies on child neurobehavioral development

Superimposed pre-eclampsia (versus chronic hypertension alone) has no adverse effect on (or slightly better) intellectual development of the offspring; however, there is no information about the antihypertensives received by the mothers during pregnancy (3). For children born small-for-gestational age, neurodevelopmental outcomes are improved if the mother develops pregnancy hypertension (102).

HDPs, and their treatment with antihypertensives, may predict generally modest long term effects on child development; clinicians should be aware of these mild disabilities and be prepared for early school-age interventions. For example, in one study, methyldopa (but not labetalol) may be associated with lower IQ; the duration of treatment being an independent negative predictor of children’s Performance IQ (3).

**Practice points**

Communities need to mobilise around the topics of pregnancy and its complications

Women, and not girls, need to enter pregnancy well-nourished and at a time of their choice.

Women require access to fully-staffed and well-resourced health facilities.

Women should be screened for the HDP, including pre-disease screening of risk.

Women with a HDP should receive personalised time-of-disease risk assessment.

All women with severe pregnancy hypertension should receive antihypertensive therapy, whether pregnant of postpartum.

All women with non-severe pregnancy hypertension should have their blood pressure normalised.

Magnesium sulphate is the agent of choice for the prevention and treatment of eclampsia as well as for fetal neuroprotection.

Decisions about delivery are gestational age-dependent.

Vaginal delivery should always be considered.

Women with any HDP, and their offspring, are at increased risk for premature cardiovascular diease.

**Research agenda**

Population-level estimates of the incidence and impact of the HDP on pregnancies.

Populations’ and decision-makers’ understanding of the HDPs to aid in identifying barriers and facilitators for future interventions.

Evaluation of the use of biomarkers, such as placental growth factor and glycosylated fibronectin to screen populations of pregnant women at increased risk for pre-eclampsia and other placental complications of pregnancy into those requiring the Edinburgh model of antenatal care, and those for whom the 4-visit model will suffice.

Identification of optimal antihypertensive to use in the setting of severe pregnancy hypertension will reduce the avoidable burden of HDP-related strokes.

Adequately-powered and well-designed studies of both reduced-dosing regimens and community administration of magnesium sulphate.

Optimal timing of delivery for pregnant women with chronic hypertension.

**Acknowledgements**

We are grateful to the following funding agencies for their support over the past two decades: the Bill & Melinda Gates Foundation, Canadian Institutes of Health Research, Saving Lives at Birth, Grand Challenges Canada, World Health Organization, US AID, International Federation of Gynecologists and Obstetricians, Rockefeller Foundation, Michael Smith Foundation for Health Research, UBC Child & Family Research Institute. BC Women’s Hospital and Health Centre, and the Society of Obstetricians and Gynaecologists of Canada. In addition, we would like to thank, in particular, the network of friends and colleagues who have led and contributed to the CHIPS, PIERS and PRE-EMPT initiatives.

**MCQs**

1. The following societal interventions are likely to reduce the impact of the hypertensive disorders of pregnancy on maternal and perinatal morbidity and mortality:
	1. Early marriage
	2. Food security for girl children and adolescents, and for women
	3. Frequent pregnancies
	4. Greater autonomy of decision-making for pregnant women
	5. Timely access to robust facilities

(A) F; (B) T; (C) F; (D) T; (E) T

Both early marriage and early pregnancy, as well as frequent pregnancies, increase a woman’s risks for developing pre-eclampsia. However, entering pregnancy at a healthy weight and well-nourished reduce those risks. For women with obstetric crises, greater autonomy of decision-making confers safety – in conservative societies that can be achieved by the granting of prior permissions by heads-of-household. All women should have ready access to facilities that are well-stocked and staffed around the clock by evidence-guided practitioners.

1. To achieve personalised medicine for women with a hypertensive disorder of pregnancy:
	1. Determining a woman’s own risk for pregnancy complications can be assessed by knowledge of demographics, symptoms and signs
	2. Women are best-advised to receive four antenatal visits in a pregnancy
	3. All women with pre-eclampsia should be delivered as soon as a diagnosis is made.
	4. Pulse oximetry will provide important information for decision-making
	5. The biophysical profile should be used to guide timing of delivery decisions

(A) T; (B) F; (C) F; (D) T; (E) F

The four-visit model will miss most women with pre-eclampsia, as it most-commonly arises between 36 weeks and delivery. The minPIERS model provides accurate and personalised risk assessment to women with pregnancy hypertension and relies solely on the knowledge of a woman’s parity, her gestational age (as best assessed), her symptoms, her blood pressure and degree of proteinuria. Pulse oximetry is very useful for assessing personalised time-of-disease risk, even screening for the risk of non-cardiorespiratory outcomes. For women <37+0 weeks of pregnancy, a policy of expectant management will improve perinatal outcomes without evidence of increased maternal risks. The use of the biophysical profile appears to increase the risks of adverse perinatal outcomes for women with pregnancies complicated by either pre-eclampsia of fetal growth restriction.

1. The following can be used for the control of pregnancy hypertension
	1. Nifedipine
	2. Methyldopa
	3. Captopril
	4. Hydralazine
	5. Lisinopril

(A) T; (B)T; (C) F; (D) T; (E) F

Neither angiotensin converting-enzyme inhibitors nor angiotensin-2 receptor-blockers should be used due to risks of stillbirth. The other agents are frequently and safely used.

1. For women with pregnancy hypertension, and their offspring, the long-term implications of pregnancy hypertension include:
	1. Similar long term cardiovascular risks as for women who remain normotensive throughout pregnancy
	2. The ability to reduce cardiovascular disease in a woman’s grandchildren through better pregnancy health for her
	3. Consistently worse neurodevelopmental outcomes for children whose mothers had a HDP
	4. Implications for the rights of girls and women
	5. A public health opportunity to intervene to reduce the burden of non-communicable diseases

(A) F; (B) T; (C) F; (D) T; (E) T

The hypertensive disorders of pregnancy identify women at increased risk for premature cardiovascular disease and related mortality. Their offspring seem to be at similarly increase4d risk. Therefore, interventions that improve the health of today’s pregnant women will improve the cardiovascular health of succeeding generations – food security for today’s girls and women matters. If anything, being born of a mother with pre-eclampsia improves long term neurodevelopmental outcomes compared with women with fetal growth restriction whose mothers remain normotensive.

**Table 1** Defining the adverse features and severe complications of pre-eclampsia (modified from Magee *et al* Preg Htn)

|  |  |  |
| --- | --- | --- |
| **Organ system affected** | **Adverse conditions**(that increase the risk of severe complications) | **Severe complications**(that warrant delivery) |
| **Central nervous system** | * Headache and/or visual symptoms
 | * Eclampsia
* PRES
* Cortical blindness or retinal detachment
* Glasgow coma scale <13
* Stroke, TIA, or RIND
 |
| **Cardiorespiratory** | * Chest pain and/or dyspnoea
* Oxygen saturation <97%
 | * Uncontrolled severe hypertension (over a period of 12hr despite use of three antihypertensive agents),
* Oxygen saturation <90%, need for ≥50% oxygen for >1hr, intubation (other than for Caesarean section)
* Pulmonary oedema
* Positive inotropic support
* Myocardial ischaemia or infarction
 |
| **Haematological** | * Elevated WBC count
* Elevated INR or aPTT
* Low platelet count
 | * Platelet count <50x109/L
* Transfusion of any blood product
 |
| **Renal** | * Elevated serum creatinine
* Elevated serum uric acid
 | * Acute kidney injury (creatinine >150µM with no prior renal disease)
* New indication for dialysis
 |
| **Hepatic** | * Nausea or vomiting
* RUQ or epigastric pain
* Elevated serum AST, ALT, LDH, or bilirubin
* Low plasma albumin
 | * Hepatic dysfunction (INR >2 in absence of DIC or warfarin)
* Hepatic haematoma or rupture
 |
| **Fetoplacental** | * Non-reassuring FHR
* IUGR
* Oligohydramnios
* Absent or reversed end-diastolic flow by Doppler velocimetry
 | * Abruption with evidence of maternal or fetal compromise
* Reverse ductus venosus A wave
* Stillbirth
 |

**AST** aspartate transaminase, **ALT** alanine transaminase, **aPTT** activated partial thromboplastin time, **DIC** disseminated intravascular coagulation, **FHR** fetal heart rate, **LDH** lactate dehydrogenase, **INR** international normalised ratio, **PRES** posterior reversible leukoencephalopathy syndrome, **RIND** reversible neurological deficit 24-48h, **RUQ** right upper quadrant, **TIA** transient ischaemic attack ≤24h, **WBC** white blood cell

**Table 2** Commonly-used agents for severe and non-severe pregnancy hypertension (modified from PvD CHR)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Indication/ Agent** | **Dosage** | **Onset** | **Peak** | **Duration** | **Comments** |
| **Severe hypertension** |
| Hydralazine | Start with 5mg iv; repeat 5–10mg iv every 3 min, or 0.5–10 mg/h iv, to a maximum of 20mg iv (or 30mg im) | 5min | 30min | 2-4h | May increase the risk of maternal hypotension. Appears less effective than nifedipine but more effective than labetalol. |
| Labetalol iv | Start with 20mg iv; repeat 20–80mg iv every 30min, or 1–2mg/min (then switch to oral [max 300 mg]) | 5min | 30min | 4h | Best avoided in women with asthma or heart failure. Neonatology should be informed if the woman is in labour, as parenteral labetalol may cause neonatal bradycardia. |
| Labetalol po | 200mg loading dose; repeat further 200mg doses every 45min (then switch to regular oral [max 1200mg/d]) | 20min - 2h | 1 - 4h | 8 - 12h (dose-dependent) |
| Nicardipine iv | Initial infusion rate 2.5 - 5mg/h, increasing by 2.5mg/h every 5 min [max 15mg/h] | 5min | 20 min | 4 - 6 h | Currently not recommended as a first line agent by any national or international guideline committee. |
| Nifedipine capsule | 5–10mg capsule to be swallowed, or bitten then swallowed, every 30min | 5 - 10min | 30min | ≈6h | Be aware of the distinction between short-acting nifedipine capsules, the intermediate-acting tablets and the slow-release tablets.Avoid nifedipine capsules in women with known coronary artery disease, severe aortic stenosis and pre-existing diabetes of ≥15y duration due to risks of acute coronary syndromes. |
| Nifedipine intermediate-acting/PA | 10mg tablet; repeat 10mg doses every 45min (then switch to regular oral medication) (max 120mg/d) | 30min | 4h | 12h |
| **Non-severe hypertension** |
| Methyldopa | 250–500mg po bid-qid (max 2g/d) | 40min | 3-6h | 12-24h | There is no evidence to support a loading dose of methyldopa. CHIPS data suggest that methyldopa is preferable to labetalol. There are reassuring neurodevelopmental data for methyldopa. |
| Labetalol | 100–400mg po bid-tid (max 1200mg/d) | 20min - 2h | 1 - 4h | 8 - 12h (dose-dependent) | Best avoided in women with asthma or heart failure. Some experts recommend a starting dose of 200mg po bid. |
| Nifedipine intermediate-acting/PA | 10-40mg tablet po bid-tid (max 120mg/d) | 30min | 4h | 12h | Be aware of the distinction between short-acting nifedipine capsules, the intermediate-acting tablets and the slow-release tablets |
| Nifedipine XL preparation | 20–60mg po OD (max 120mg/d)) | 60min | 6h | 24h |

Reference List

 (1) Mol BW, Roberts CT, Thangaratinam S, Magee LA, de Groot CJ, Hofmeyr GJ. Pre-eclampsia. Lancet 2015 September 2.

 (2) Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010 August 21;376(9741):631-44.

 (3) Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens 2014 April;4(2):105-45.

 (4) Martin JN, Jr., Thigpen BD, Moore RC, Rose CH, Cushman J, May W. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol 2005 February;105(2):246-54.

 (5) Schutte JM, Schuitemaker NW, van Roosmalen J, Steegers EA. Substandard care in maternal mortality due to hypertensive disease in pregnancy in the Netherlands. BJOG 2008 May;115(6):732-6.

 (6) Lewis, G. Saving mothers' lives: reviewing maternal deaths to make motherhood safer. The 7th report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. London: Confidential Enquiry into Maternal and Child Health; 2007.

 (7) Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D et al. Saving Mothers' Lives: Reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011 March;118 Suppl 1:1-203.

 (8) Cote AM, Firoz T, Mattman A, Lam EM, von Dadelszen P, Magee LA. The 24-hour urine collection: gold standard or historical practice? Am J Obstet Gynecol 2008 December;199(6):625-6.

 (9) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002 February;39(2 Suppl 1):S1-266.

 (10) Payne BA, Hutcheon JA, Ansermino JM, Hall DR, Bhutta ZA, Bhutta SZ et al. A risk prediction model for the assessment and triage of women with hypertensive disorders of pregnancy in low-resourced settings: the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) multi-country prospective cohort study. PLoS Med 2014 January;11(1):e1001589.

 (11) von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton PF, Cote AM et al. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet 2011 January 15;377(9761):219-27.

 (12) Gruslin A, Lemyre B. Pre-eclampsia: fetal assessment and neonatal outcomes. Best Pract Res Clin Obstet Gynaecol 2011 August;25(4):491-507.

 (13) Knight M. Eclampsia in the United Kingdom 2005. BJOG 2007 September;114(9):1072-8.

 (14) Kassebaum NJ, Bertozzi-Villa A, Coggeshall MS, Shackelford KA, Steiner C, Heuton KR et al. Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014 September 13;384(9947):980-1004.

 (15) Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 2011 August;25(4):391-403.

 (16) Thaddeus S, Maine D. Too far to walk: maternal mortality in context. Soc Sci Med 1994 April;38(8):1091-110.

 (17) Lotufo FA, Parpinelli MA, Haddad SM, Surita FG, Cecatti JG. Applying the new concept of maternal near-miss in an intensive care unit. Clinics (Sao Paulo) 2012;67(3):225-30.

 (18) Naderi T, Foroodnia S, Omidi S, Samadani F, Nakhaee N. Incidence and correlates of maternal near miss in southeast iran. Int J Reprod Med 2015;2015:914713.

 (19) Tuncalp O, Hindin MJ, Souza JP, Chou D, Say L. The prevalence of maternal near miss: a systematic review. BJOG 2012 May;119(6):653-61.

 (20) Lawn JE, Blencowe H, Waiswa P, Amouzou A, Mathers C, Hogan D et al. Stillbirths: rates, risk factors, and acceleration towards 2030. Lancet 2016 February 6;387(10018):587-603.

 (21) Vogel JP, Souza JP, Mori R, Morisaki N, Lumbiganon P, Laopaiboon M et al. Maternal complications and perinatal mortality: findings of the World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG 2014 March;121 Suppl 1:76-88.

 (22) Lawn JE, Blencowe H, Oza S, You D, Lee AC, Waiswa P et al. Every Newborn: progress, priorities, and potential beyond survival. Lancet 2014 July 12;384(9938):189-205.

 (23) Backes CH, Markham K, Moorehead P, Cordero L, Nankervis CA, Giannone PJ. Maternal preeclampsia and neonatal outcomes. J Pregnancy 2011;2011:214365.

 (24) Pijnenborg R, Anthony J, Davey DA, Rees A, Tiltman A, Vercruysse L et al. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 1991 July;98(7):648-55.

 (25) Roberts JM, Escudero C. The placenta in preeclampsia. Pregnancy Hypertens 2012 April 1;2(2):72-83.

 (26) Mason E, Chandra-Mouli V, Baltag V, Christiansen C, Lassi ZS, Bhutta ZA. Preconception care: advancing from 'important to do and can be done' to 'is being done and is making a difference'. Reprod Health 2014 September 26;11 Suppl 3:S8.

 (27) Prost A, Colbourn T, Seward N, Azad K, Coomarasamy A, Copas A et al. Women's groups practising participatory learning and action to improve maternal and newborn health in low-resource settings: a systematic review and meta-analysis. Lancet 2013 May 18;381(9879):1736-46.

 (28) Colbourn T, Nambiar B, Bondo A, Makwenda C, Tsetekani E, Makonda-Ridley A et al. Effects of quality improvement in health facilities and community mobilization through women's groups on maternal, neonatal and perinatal mortality in three districts of Malawi: MaiKhanda, a cluster randomized controlled effectiveness trial. Int Health 2013 September;5(3):180-95.

 (29) Khowaja AR, Mitton C, Bryan S, Magee LA, Bhutta ZA, von Dadelszen P. Economic evaluation of Community Level Interventions for Pre-eclampsia (CLIP) in South Asian and African countries: a study protocol. Implement Sci 2015;10:76.

 (30) Basso O, Wilcox AJ, Weinberg CR, Baird DD, Olsen J. Height and risk of severe pre-eclampsia. A study within the Danish National Birth Cohort. Int J Epidemiol 2004 August;33(4):858-63.

 (31) Sohlberg S, Stephansson O, Cnattingius S, Wikstrom AK. Maternal body mass index, height, and risks of preeclampsia. Am J Hypertens 2012 January;25(1):120-5.

 (32) Dean SV, Lassi ZS, Imam AM, Bhutta ZA. Preconception care: nutritional risks and interventions. Reprod Health 2014 September 26;11 Suppl 3:S3.

 (33) Ahmed T, Mahfuz M, Ireen S, Ahmed AM, Rahman S, Islam MM et al. Nutrition of children and women in Bangladesh: trends and directions for the future. J Health Popul Nutr 2012 March;30(1):1-11.

 (34) Laraia BA, Siega-Riz AM, Gundersen C. Household food insecurity is associated with self-reported pregravid weight status, gestational weight gain, and pregnancy complications. J Am Diet Assoc 2010 May;110(5):692-701.

 (35) Poston L, Chappell LC. Is oxidative stress involved in the aetiology of pre-eclampsia? Acta Paediatr Suppl 2001 March;90(436):3-5.

 (36) Rumbold A, Ota E, Nagata C, Shahrook S, Crowther CA. Vitamin C supplementation in pregnancy. Cochrane Database Syst Rev 2015;9:CD004072.

 (37) Rumbold A, Ota E, Hori H, Miyazaki C, Crowther CA. Vitamin E supplementation in pregnancy. Cochrane Database Syst Rev 2015;9:CD004069.

 (38) Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 2014;6:CD001059.

 (39) Hofmeyr GJ, Belizan JM, von Dadelszen P. Low-dose calcium supplementation for preventing pre-eclampsia: a systematic review and commentary. BJOG 2014 July;121(8):951-7.

 (40) Hofmeyr GJ, Seuc AH, Betran AP, Purnat TD, Ciganda A, Munjanja SP et al. The effect of calcium supplementation on blood pressure in non-pregnant women with previous pre-eclampsia: An exploratory, randomized placebo controlled study. Pregnancy Hypertens 2015 October;5(4):273-9.

 (41) Agrawal S, Fledderjohann J, Vellakkal S, Stuckler D. Adequately diversified dietary intake and iron and folic acid supplementation during pregnancy is associated with reduced occurrence of symptoms suggestive of pre-eclampsia or eclampsia in Indian women. PLoS One 2015;10(3):e0119120.

 (42) Bhutta ZA, Das JK, Rizvi A, Gaffey MF, Walker N, Horton S et al. Evidence-based interventions for improvement of maternal and child nutrition: what can be done and at what cost? Lancet 2013 August 3;382(9890):452-77.

 (43) Leppalahti S, Gissler M, Mentula M, Heikinheimo O. Is teenage pregnancy an obstetric risk in a welfare society? A population-based study in Finland, from 2006 to 2011. BMJ Open 2013;3(8):e003225.

 (44) Kumar A, Singh T, Basu S, Pandey S, Bhargava V. Outcome of teenage pregnancy. Indian J Pediatr 2007 October;74(10):927-31.

 (45) Aliyu MH, Luke S, Kristensen S, Alio AP, Salihu HM. Joint effect of obesity and teenage pregnancy on the risk of preeclampsia: a population-based study. J Adolesc Health 2010 January;46(1):77-82.

 (46) Saftlas AF, Rubenstein L, Prater K, Harland KK, Field E, Triche EW. Cumulative exposure to paternal seminal fluid prior to conception and subsequent risk of preeclampsia. J Reprod Immunol 2014 March;101-102:104-10.

 (47) Staff AC, Benton SJ, von Dadelszen P, Roberts JM, Taylor RN, Powers RW et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertension 2013 May;61(5):932-42.

 (48) de Jonge HC, Azad K, Seward N, Kuddus A, Shaha S, Beard J et al. Determinants and consequences of short birth interval in rural Bangladesh: a cross-sectional study. BMC Pregnancy Childbirth 2014;14:427.

 (49) United Nations Population Fund. RHCS update: the Global Programme to Enhance Reproductive Health Commodity Security. New York: UNFPA; 2010.

 (50) Neira M, Kelley E, Bahl R, Chopra M, Wijesekera S. Water, sanitation and hygiene in health care facilities: status in low and middle income countries and way forward. Geneva: World Health Organization; 2015.

 (51) Campbell OM, Benova L, Gon G, Afsana K, Cumming O. Getting the basic rights - the role of water, sanitation and hygiene in maternal and reproductive health: a conceptual framework. Trop Med Int Health 2015 March;20(3):252-67.

 (52) Chweya L. Democracy and organization of local governance in Kenya. In: Chitere OP, Mutiso R, editors. Working with rural communities: participatory action research in Kenya. 2nd ed. Nairobi: University of Nairobi Press; 2014. p. 203-36.

 (53) ten Hoope-Bender P, de Bernis L, Campbell J, Downe S, Fauveau V, Fogstad H et al. Improvement of maternal and newborn health through midwifery. Lancet 2014 September 27;384(9949):1226-35.

 (54) Mother-baby friendly birthing facilities. Int J Gynaecol Obstet 2015 February;128(2):95-9.

 (55) Miller S, Lalonde A. The global epidemic of abuse and disrespect during childbirth: History, evidence, interventions, and FIGO's mother-baby friendly birthing facilities initiative. Int J Gynaecol Obstet 2015 October;131 Suppl 1:S49-S52.

 (56) Moyer CA, Adongo PB, Aborigo RA, Hodgson A, Engmann CM. 'They treat you like you are not a human being': maltreatment during labour and delivery in rural northern Ghana. Midwifery 2014 February;30(2):262-8.

 (57) Rasanen J, Quinn MJ, Laurie A, Bean E, Roberts CT, Jr., Nagalla SR et al. Maternal serum glycosylated fibronectin as a point-of-care biomarker for assessment of preeclampsia. Am J Obstet Gynecol 2015 January;212(1):82-9.

 (58) Widmer M, Cuesta C, Khan KS, Conde-Agudelo A, Carroli G, Fusey S et al. Accuracy of angiogenic biomarkers at 20weeks' gestation in predicting the risk of pre-eclampsia: A WHO multicentre study. Pregnancy Hypertens 2015 October;5(4):330-8.

 (59) Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004 December;104(6):1367-91.

 (60) Lassi ZS, Mansoor T, Salam RA, Das JK, Bhutta ZA. Essential pre-pregnancy and pregnancy interventions for improved maternal, newborn and child health. Reprod Health 2014;11 Suppl 1:S2.

 (61) Dowswell T, Carroli G, Duley L, Gates S, Gulmezoglu AM, Khan-Neelofur D et al. Alternative versus standard packages of antenatal care for low-risk pregnancy. Cochrane Database Syst Rev 2015;7:CD000934.

 (62) Oakley A. Origins and development of antenatal care. Effectiveness and satisfaction with antenatal care.Cambridge: Cambridge University Press; 1982. p. 1-21.

 (63) von Dadelszen P, Magee LA. Pre-eclampsia: an update. Curr Hypertens Rep 2014 August;16(8):454.

 (64) Magee LA, Abalos E, von Dadelszen P, Sibai B, Easterling T, Walkinshaw S. How to manage hypertension in pregnancy effectively. Br J Clin Pharmacol 2011 September;72(3):394-401.

 (65) Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 1995 June 10;345(8963):1455-63.

 (66) Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002 June 1;359(9321):1877-90.

 (67) Fernando D, Jayatilleka A, Karunaratna V. Pregnancy--reducing maternal deaths and disability in Sri Lanka: national strategies. Br Med Bull 2003;67:85-98.

 (68) Gillon TE, Pels A, von Dadelszen P, MacDonell K, Magee LA. Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines. PLoS One 2014;9(12):e113715.

 (69) Nathan HL, de GA, Hezelgrave NL, Chappell LC, Shennan AH. An accurate semiautomated oscillometric blood pressure device for use in pregnancy (including pre-eclampsia) in a low-income and middle-income country population: the Microlife 3AS1-2. Blood Press Monit 2015 February;20(1):52-5.

 (70) Wen SW, Kramer MS, Hoey J, Hanley JA, Usher RH. Terminal digit preference, random error, and bias in routine clinical measurement of blood pressure. J Clin Epidemiol 1993 October;46(10):1187-93.

 (71) Morris RK, Riley RD, Doug M, Deeks JJ, Kilby MD. Diagnostic accuracy of spot urinary protein and albumin to creatinine ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: systematic review and meta-analysis. BMJ 2012;345:e4342.

 (72) De Silva DA, Halstead AC, Cote AM, Sabr Y, von DP, Magee LA. Random urine albumin:creatinine ratio in high-risk pregnancy - Is it clinically useful? Pregnancy Hypertens 2013 April;3(2):112-4.

 (73) Payne B, Magee LA, Cote AM, Hutcheon JA, Li J, Kyle PM et al. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can 2011 June;33(6):588-97.

 (74) Kozic JR, Benton SJ, Hutcheon JA, Payne BA, Magee LA, von Dadelszen P. Abnormal liver function tests as predictors of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can 2011 October;33(10):995-1004.

 (75) Laskin S, Payne B, Hutcheon JA, Qu Z, Douglas MJ, Ford J et al. The role of platelet counts in the assessment of inpatient women with preeclampsia. J Obstet Gynaecol Can 2011 September;33(9):900-8.

 (76) Livingston JR, Payne B, Brown M, Roberts JM, Cote AM, Magee LA et al. Uric Acid as a predictor of adverse maternal and perinatal outcomes in women hospitalized with preeclampsia. J Obstet Gynaecol Can 2014 October;36(10):870-7.

 (77) Millman AL, Payne B, Qu Z, Douglas MJ, Hutcheon JA, Lee T et al. Oxygen saturation as a predictor of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can 2011 July;33(7):705-14.

 (78) Yen TW, Payne B, Qu Z, Hutcheon JA, Lee T, Magee LA et al. Using clinical symptoms to predict adverse maternal and perinatal outcomes in women with preeclampsia: data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) study. J Obstet Gynaecol Can 2011 August;33(8):803-9.

 (79) Payne BA, Hutcheon JA, Dunsmuir D, Cloete G, Dumont G, Hall D et al. Assessing the incremental value of blood oxygen saturation (SpO(2)) in the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) Risk Prediction Model. J Obstet Gynaecol Can 2015 January;37(1):16-24.

 (80) Dunsmuir DT, Payne BA, Cloete G, Petersen CL, Gorges M, Lim J et al. Development of mHealth applications for pre-eclampsia triage. IEEE J Biomed Health Inform 2014 November;18(6):1857-64.

 (81) Lim J, Cloete G, Dunsmuir DT, Payne BA, Scheffer C, von Dadelszen P et al. Usability and feasibility of PIERS on the Move: an mHealth app for pre-eclampsia triage. JMIR Mhealth Uhealth 2015;3(2):e37.

 (82) Payne B, Hodgson S, Hutcheon JA, Joseph KS, Li J, Lee T et al. Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission. BJOG 2013 January;120(1):113-8.

 (83) Akkermans J, Payne B, von Dadelszen P, Groen H, de Vries J, Magee LA et al. Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset. Eur J Obstet Gynecol Reprod Biol 2014 August;179:58-62.

 (84) Agrawal S, Maitra N. Prediction of adverse maternal outcomes in preeclampsia using a risk prediction model. J Obstet Gynecol India 2015;Epub ahead of print:1-8.

 (85) Winje BA, Wojcieszek AM, Gonzalez-Angulo LY, Teoh Z, Norman J, Froen JF et al. Interventions to enhance maternal awareness of decreased fetal movement: a systematic review. BJOG 2015 December 2.

 (86) Payne BA, Groen H, Ukah UV, Ansermino JM, Bhutta Z, Grobman W et al. Development and internal validation of a multivariable model to predict perinatal death in pregnancy hypertension. Pregnancy Hypertens 2015 October;5(4):315-21.

 (87) Grivell RM, Wong L, Bhatia V. Regimens of fetal surveillance for impaired fetal growth. Cochrane Database Syst Rev 2012;6:CD007113.

 (88) Kaur S, Picconi JL, Chadha R, Kruger M, Mari G. Biophysical profile in the treatment of intrauterine growth-restricted fetuses who weigh <1000 g. Am J Obstet Gynecol 2008 September;199(3):264.

 (89) Payne BA, Kyle PM, Lim K, Lisonkova S, Magee LA, Pullar B et al. An assessment of predictive value of the biophysical profile in women with preeclampsia using data from the fullPIERS database. Pregnancy Hypertens 2013 July;3(3):166-71.

 (90) Shalev E, Zalel Y, Weiner E. A comparison of the nonstress test, oxytocin challenge test, Doppler velocimetry and biophysical profile in predicting umbilical vein pH in growth-retarded fetuses. Int J Gynaecol Obstet 1993 October;43(1):15-9.

 (91) Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med 2015 January 29;372(5):407-17.

 (92) Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S et al. Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. BJOG 2015 August 11.

 (93) Lalani S, Firoz T, Magee LA, Sawchuck D, Payne B, Gordon R et al. Pharmacotherapy for preeclampsia in low and middle income countries: an analysis of essential medicines lists. J Obstet Gynaecol Can 2013 March;35(3):215-23.

 (94) Gordon R, Magee LA, Payne B, Firoz T, Sawchuck D, Tu D et al. Magnesium sulphate for the management of preeclampsia and eclampsia in low and middle income countries: a systematic review of tested dosing regimens. J Obstet Gynaecol Can 2014 February;36(2):154-63.

 (95) Bickford CD, Magee LA, Mitton C, Kruse M, Synnes AR, Sawchuck D et al. Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis. BMC Health Serv Res 2013;13:527.

 (96) Magee L, Sawchuck D, Synnes A, von Dadelszen P. SOGC Clinical Practice Guideline. Magnesium sulphate for fetal neuroprotection. J Obstet Gynaecol Can 2011 May;33(5):516-29.

 (97) Althabe F, Belizan JM, McClure EM, Hemingway-Foday J, Berrueta M, Mazzoni A et al. A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomised trial. Lancet 2015 February 14;385(9968):629-39.

 (98) Crowther CA, McKinlay CJ, Middleton P, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database Syst Rev 2015;7:CD003935.

 (99) Hutcheon JA, Lisonkova S, Magee LA, von Dadelszen P, Woo HL, Liu S et al. Optimal timing of delivery in pregnancies with pre-existing hypertension. BJOG 2011 January;118(1):49-54.

 (100) Ganzevoort W, Sibai BM. Temporising versus interventionist management (preterm and at term). Best Pract Res Clin Obstet Gynaecol 2011 August;25(4):463-76.

 (101) Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 2001 November 24;323(7323):1213-7.

 (102) McCowan LM, Pryor J, Harding JE. Perinatal predictors of neurodevelopmental outcome in small-for-gestational-age children at 18 months of age. Am J Obstet Gynecol 2002 May;186(5):1069-75.